Park says patient-specific factors that influence his treatment selection include the presence of liver disease, ...

Based on patterns of recurrence-free survival (RFS) over time in some studies, the researchers determined that 5-year RFS may be a suitable surrogate for measuring cure.

Patients with urinary stones show poorer survival in upper tract urothelial carcinoma. Find out how stone history may affect ...

A groundbreaking new study has found that a combination of two drugs can boost survival rates in prostate cancer patients by ...

Throughout October, CURE highlighted research developments and evolving treatment strategies that continue to shape cancer ...

Investigators have developed a prognostic model that may identify which patients with MIBC are suitable for bladder-preserving chemoradiation.

Muscle-invasive bladder cancer management is challenging for cisplatin-ineligible patients due to limited treatment options and high recurrence rates. The Padcev-Keytruda combination therapy ...

Young cancer, rising health costs, and financial strain are reshaping America's healthcare system as more people under 50 ...

HAMLET BioPharma, a clinical-stage biopharmaceutical company advancing targeted oncological and other therapies, today announced it has received written feedback from the U.S. Food and Drug ...

Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety ...

Discover how scientists are engineering bacteria to fight cancer by targeting tumors, enhancing immune response, and ...

By now, you know that the COVID-19 vaccine is the best way to protect against severe COVID infections and reduce your chances of developing long COVID. You also know that the COVID-19 vaccine may have ...